Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer

September 17th 2021

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Promising Results Push Nivolumab/Chemotherapy Forward in Gastric Cancer

September 15th 2021

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer

September 11th 2021

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma

July 29th 2021

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

Investigators Explore the Role of VS-6766 and Defactinib in KRAS-Mutant NSCLC

July 21st 2021

Patients with non-small cell lung cancer harboring KRAS mutations have been an underserved population with few treatment options, specifically those with G12V mutations.

Dostarlimab Expands Options for dMMR Endometrial Cancer

July 14th 2021

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Copanlisib/Rituximab Combination Demonstrates Superiority Across iNHL

July 9th 2021

Copanlisib plus rituximab exhibited a manageable safety profile and superior efficacy in patients with relapsed indolent non-Hodgkin lymphoma (iNHL) compared with rituximab plus placebo.

New Toolkit Aims to Help Employers Address Cancer Treatment

July 8th 2021

The National Comprehensive Cancer Network (NCCN) has launched a digital initiative to provide strategic approaches specifically geared toward employers who need to navigate a diagnosis of cancer among their staff.

The Understanding of Immunotherapy Biomarkers Is Rapidly Evolving in Oncology

June 29th 2021

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

Isatuximab Combination Looks to Improve Outcomes for Early Relapsed Multiple Myeloma

June 28th 2021

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

Axi-cel Elicits Durable Response in Relapsed/Refractory FL

June 16th 2021

Henry Chi Hang Fung, MD, discusses how the durable response of axi-cel fills an unmet need for this patient population and the potentially exciting future of the therapy.

Kaiku Health and Novartis Collaborate on Specialized Digital Patient Monitoring Technology

June 15th 2021

Kaiku Health has announced that they are partnering with the global healthcare company Novartis to develop a digital patient monitoring and management system specifically for patients with melanoma who are receiving BRAF/MEK combination therapies.

Front-MIND Aims to Examine Tafasitamab Triplet in DLBCL

June 14th 2021

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.